The Clinical Trial of Cefuroxime Axetil Dispersible Tablets

Brief Summary: 1. National, large-scale, standardized, standardized, real-world research;

2. Prospective, single - arm open, non - interventional, registration, multi - center clinical study;

3. in the use of cefuroxime axetil dispersible tablets in the hospital, according to the principle of voluntary selection of 200;

4. registration of the use of cefuroxime axetil dispersion tablets patients;

5. Target sample size of 100,000 cases;

6. Exemption from informed consent for ethical review applications;

7. Antibiotic drug safety re-evaluation of large data.

Detailed Description: Research purposes

1. To evaluate the safety of cefuroxime axetil dispersible tablets in the real world of the widely used population,

Rare or even very rare, new, unanticipated adverse reactions, while revealing adverse reactions

Should be susceptible to risk factors and susceptible populations.

2. To evaluate the efficacy of cefuroxime axetil dispersible tablets in the treatment of the relevant site of infection, including

Including empirical therapy and targeted therapy, to further evaluate the widespread use of cefuroxime dispersible tablets

The validity of the crowd in the real world.

3. To investigate the clinical application of cefuroxime axetil dispersible tablets for the safety management of drug use.

Clinical management should provide more clinical clues and basis.

4. For the relevant treatment areas of guidance and consensus revision, clinical pathway design provides a reference.

5. To further improve the safety of cefuroxime axetil dispersion tablets level, the basic medical security capabilities and Market vitality.

Study end point

1. The main study endpoint:

* Security;

* Effectiveness.

2. Secondary study endpoint:

* Extensive use of population characteristics;

* Clinical drug characteristics;

* Appropriate characteristics of the crowd;

* Adverse reactions susceptible population characteristics.

Recruitment & Eligibility

Inclusion Criteria

Exclusion Criteria

Primary Outcome Measures

Name	Time	Method
Bacterial clearance	1 to 14 days after the use of Cefuroxime Axetil Dispersible Tablets，	1.clear 2.Assume purge 3.Not cleared 4.Assume not cleared 5.Partially cleared 6.replace 7.Re-infection 8.Colonization 9.Can not be evaluated

Secondary Outcome Measures

Name	Time	Method

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial